DRIO
DarioHealth Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$7.20
+3.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.03
From 52W high−58.50%
Volume19684.00
Market cap$70.56M
P/E (TTM)10.4x
P/S (TTM)3.4x
Div yield—
Key dataSep 18, 2026
Open
$7.03
From 52W high
−58.50%
Volume
19684.00
Market cap
$70.56M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
P/E (TTM)
10.4x
RSI (14)
50.5
MomentumView details →
1D Return
+3.00%
YTD Return
−37.70%
SummaryUpdated Jun 1, 2026
DarioHealth Corp. (NASDAQ:DRIO) is a digital therapeutics company that has undergone significant transformation since its founding. Originally incorporated in 2011 as LabStyle Innovations Corp., the company changed its name to DarioHealth Corp. in July 2016 and went public the same year. Based in New York, DarioHealth has evolved from a direct-to-consumer diabetes management company into a comprehensive digital health platform serving multiple chronic conditions through business-to-business partnerships with employers, health plans, and pharmaceutical companies across the United States, Canada, European Union, Australia, and New Zealand.
Similar companies
Latest newsMore news →
DarioHealth Corp. announced a new contract with a leading New Jersey health plan covering approximately 1.5 million lives, secured through channel partner Amwell, with its cardiometabolic suite and provider-backed care expected to launch and begin generating revenue in the first quarter of 2027.3d agoLawrence Leisure retired as Director of DarioHealth Corp., effective September 2, 2026.16d agoDarioHealth Corp. appointed Steven Nelson as Independent Consultant, effective October 1, 2026, with a grant of 30,000 shares of restricted common stock vesting on the first anniversary or upon a Change in Control.31d ago